Potential for Cancer Related Health Services Research Using a Linked Medicare-Tumor Registry Database

Potosky, Arnold L.; Riley, Gerald F.; Lubitz, James; Mentnech, Renee; Kessler, Larry G.

doi:10.1097/00005650-199308000-00006

Cited by 673 publications

(457 citation statements)

References 51 publications

Supporting

Mentioning

452

Contrasting

Order By: Relevance

“…All incident cancer patients reported to the SEER registries are cross-matched with Medicare enrollment and claims files 24 . We selected patients 67-94-years-old diagnosed with initial invasive primary CRC from 1993 through 2002 (Appendix 1).…”

Section: Methodsmentioning

confidence: 99%

Assessing the Impact of Screening Colonoscopy on Mortality in the Medicare Population

et al. 2011

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

Assessing the Impact of Screening Colonoscopy on Mortality in the Medicare Population

et al. 2011

View full text Add to dashboard Cite

“…10,11 The SEER program collects cancer incidence and survival data from population-based cancer registries, covering 14-26% of the US population. SEER data included information on patient demographics, date of cancer diagnosis and tumor stage.…”

Section: Data Sourcementioning

confidence: 99%

Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999–2006

Sathiakumar

Delzell

Morrisey

et al. 2011

Prostate Cancer Prostatic Dis

191

148

View full text Add to dashboard Cite

Information on the impact of bone metastasis and skeletal-related events (SREs) on mortality among prostate cancer patients is limited. Using the linked Surveillance, Epidemiology and End Results (SEER)-Medicare database, we identified men aged 65 years or older diagnosed with prostate cancer between July 1 1999 and December 31 2005 and followed to determine deaths through December 31 2006. We classified subjects as having bone metastasis and SREs as indicated by Medicare claims. Using Cox regression, we estimated mortality hazards ratios (HR) among men with bone metastasis with or without SRE, compared with men without bone metastasis. Among 126 978 men with prostate cancer (median follow-up, 3.3 years), 9746 (7.7%) had bone metastasis at prostate cancer diagnosis (1.7%) or during follow-up (5.9%). SREs occurred in 4296 (44%) men with bone metastasis. HRs for risk of death were 6.6 (95% CI ¼ 6.4-6.9) and 10.2 (95% CI ¼ 9.8-10.7), respectively, for men with bone metastasis but no SRE and for men with bone metastasis plus SRE, compared with men without bone metastasis. Bone metastasis was associated with mortality among prostate cancer patients. This association appeared to be stronger for bone metastasis plus SRE than for bone metastasis without SRE.

show abstract

“…29 We identified 77,038 males aged >65 years with a first primary diagnosis of prostate cancer between 1995 and 2005 and living in one of the SEER-13 regions that covered approximately 14% of the US population. 30 All individuals were white or black, enrolled in parts A and B of fee-for-service Medicare from at least 1 year before through 6 months after diagnosis, and not diagnosed by autopsy or death certificate.…”

Section: Data and Patientsmentioning

confidence: 99%

Explaining racial differences in prostate cancer mortality

Taksler

Keating

Cutler

2012

Cancer

View full text Add to dashboard Cite

BACKGROUND:In the United States, black males have an annual death rate from prostate cancer that is 2.4 times that of white males. The reasons for this are poorly understood. METHODS: Using the Surveillance, Epidemiology, and End Results-Medicare database, 77,038 black and white males aged >65 years were identified with a first primary diagnosis of prostate cancer between 1995 and 2005, as well as 49,769 controls. The racial gap in mortality was decomposed to differential incidence and stage-specific prostate cancer mortality. The importance of various clinical and socioeconomic factors to each of these components was then examined. RESULTS: The estimated mortality gap for prostate cancer-specific mortality was 1320 more cases per 100,000 males among black than white men. This gap was due to higher prostate cancer incidence among black males (76%) and higher stage-specific mortality once diagnosed (24%). Differences in prostate-specific antigen testing, comorbidities, and income explained 29% of the difference in metastatic cancer incidence but none of the racial gap for local/regional incidence. Conditional on diagnosis, tumor characteristics explained 50% of the racial gap, comorbidities an additional 4%, choice of treatment and physician 17%, and socioeconomic factors 15%. Overall, approximately 25% of the racial gap in mortality and 86% of the gap in mortality conditional on diagnosis could be explained. CONCLUSIONS: More frequent prostate-specific antigen testing for black and low-income males could potentially reduce the prostate cancer mortality gap through earlier diagnosis of tumors that otherwise may become metastatic. More aggressive treat-

show abstract

Potential for Cancer Related Health Services Research Using a Linked Medicare-Tumor Registry Database

Cited by 673 publications

References 51 publications

Assessing the Impact of Screening Colonoscopy on Mortality in the Medicare Population

Assessing the Impact of Screening Colonoscopy on Mortality in the Medicare Population

Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999–2006

Explaining racial differences in prostate cancer mortality

Contact Info

Product

Resources

About